Phase 2 Study of Resunab to Treat Systemic Sclerosis Now Fully Enrolled, Corbus Reports
Corbus Pharmaceuticals recently announced that its Phase 2 clinical trial assessing the drug Resunab as a potential treatment for diffuse cutaneous systemic sclerosis is now fully enrolled. The study (NCT02465437) is a randomized, double-blind and placebo-control trial, taking place at nine sites across the U.S., to evaluate Resunab’s efficacy, tolerability, safety and pharmacokinetics…